+

PL3265448T3 - Proleki riluzolu i ich zastosowanie - Google Patents

Proleki riluzolu i ich zastosowanie

Info

Publication number
PL3265448T3
PL3265448T3 PL16759303T PL16759303T PL3265448T3 PL 3265448 T3 PL3265448 T3 PL 3265448T3 PL 16759303 T PL16759303 T PL 16759303T PL 16759303 T PL16759303 T PL 16759303T PL 3265448 T3 PL3265448 T3 PL 3265448T3
Authority
PL
Poland
Prior art keywords
prolocks
rilusol
application
rilusol prolocks
Prior art date
Application number
PL16759303T
Other languages
English (en)
Inventor
Jay Edward Wrobel
Allen B. Reitz
Jeffery Claude Pelletier
Garry Robert Smith
Haiyan Bian
Original Assignee
Biohaven Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd. filed Critical Biohaven Therapeutics Ltd.
Publication of PL3265448T3 publication Critical patent/PL3265448T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36Immune checkpoint inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
PL16759303T 2015-03-03 2016-02-26 Proleki riluzolu i ich zastosowanie PL3265448T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127684P 2015-03-03 2015-03-03
PCT/US2016/019787 WO2016140879A1 (en) 2015-03-03 2016-02-26 Riluzole prodrugs and their use
EP16759303.7A EP3265448B1 (en) 2015-03-03 2016-02-26 Riluzole prodrugs and their use

Publications (1)

Publication Number Publication Date
PL3265448T3 true PL3265448T3 (pl) 2022-04-25

Family

ID=56848452

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16759303T PL3265448T3 (pl) 2015-03-03 2016-02-26 Proleki riluzolu i ich zastosowanie

Country Status (24)

Country Link
US (9) US10639298B2 (pl)
EP (2) EP4011870A1 (pl)
JP (2) JP6700293B2 (pl)
KR (2) KR20230147746A (pl)
CN (1) CN107567438B (pl)
AU (3) AU2016226463B2 (pl)
BR (1) BR112017018832B1 (pl)
CA (1) CA2978158C (pl)
CY (1) CY1125112T1 (pl)
DK (1) DK3265448T3 (pl)
EA (1) EA034759B1 (pl)
ES (1) ES2905318T3 (pl)
HR (1) HRP20220208T1 (pl)
HU (1) HUE058204T2 (pl)
IL (2) IL253989B (pl)
LT (1) LT3265448T (pl)
MX (1) MX380828B (pl)
PH (2) PH12021550250A1 (pl)
PL (1) PL3265448T3 (pl)
PT (1) PT3265448T (pl)
RS (1) RS62915B1 (pl)
SG (2) SG11201706831RA (pl)
SI (1) SI3265448T1 (pl)
WO (2) WO2016140878A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
EP3616686B8 (en) * 2014-11-21 2021-06-23 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
SG11201706831RA (en) 2015-03-03 2017-09-28 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
JP2017061430A (ja) * 2015-09-25 2017-03-30 芳男 ▲浜▼田 新規なプロドラッグ
SI4019019T1 (sl) * 2016-05-20 2024-07-31 Biohaven Therapeutics Ltd. Uporaba riluzola, predzdravil riluzola ali analogov riluzola z imunoterapijami za zdravljenje rakov
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
HUE052854T2 (hu) * 2016-11-25 2021-05-28 Genuv Inc Készítmény a neurális õssejtek differenciálódásának elõsegítésére és védelmére, továbbá módszer a neurális regeneráció indukálására ugyanennek a segítségével
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US12201618B2 (en) * 2017-01-18 2025-01-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat Alzheimer's disease
US20180207138A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
CN113061144A (zh) * 2017-02-28 2021-07-02 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物
CN107021959A (zh) * 2017-05-02 2017-08-08 青岛科技大学 一类新型吲哚衍生物及其体外抗肿瘤活性
PL3706739T3 (pl) * 2017-11-12 2025-03-10 Biohaven Therapeutics Ltd. Zastosowanie proleków riluzolu do leczenia ataksji
AU2019310013B2 (en) * 2018-07-22 2025-01-02 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
JP2021534160A (ja) * 2018-08-16 2021-12-09 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. 疾患処置のためのリルゾール口腔内崩壊錠の使用
GB201818651D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds
US20240067651A1 (en) * 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
PH12022553441A1 (en) * 2020-06-24 2024-03-04 Biohaven Therapeutics Ltd Compositions and methods for treating obsessive-compulsive disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
IL305326A (en) * 2021-02-22 2023-10-01 Univ Yale Targeted bifunctional degraders and methods using same
KR102785404B1 (ko) 2022-08-19 2025-03-21 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用
WO2024006678A1 (en) * 2022-06-26 2024-01-04 Biohaven Therapeutics Ltd. Methods of treating glioblastoma with prodrugs of riluzole
CN118085016B (zh) * 2024-04-24 2024-07-30 天津卡普希科技有限公司 一种d-苯甘氨酰-甘氨酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043319B1 (en) * 1997-11-05 2005-03-16 Mitsubishi Chemical Corporation Novel alkylamino derivatives
BR0210391A (pt) * 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
WO2006009134A1 (ja) * 2004-07-21 2006-01-26 Mitsui Chemicals, Inc. ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤
SI2982372T1 (sl) 2005-04-05 2020-11-30 Yale University, Office of Cooperative Research Sredstva za modulacijo glutamata pri zdravljenju mentalnih motenj
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
US12295942B2 (en) * 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
SG11201706831RA (en) * 2015-03-03 2017-09-28 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use
WO2017087594A1 (en) 2015-11-19 2017-05-26 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds
SI4019019T1 (sl) * 2016-05-20 2024-07-31 Biohaven Therapeutics Ltd. Uporaba riluzola, predzdravil riluzola ali analogov riluzola z imunoterapijami za zdravljenje rakov
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
PL3706739T3 (pl) 2017-11-12 2025-03-10 Biohaven Therapeutics Ltd. Zastosowanie proleków riluzolu do leczenia ataksji

Also Published As

Publication number Publication date
ES2905318T3 (es) 2022-04-07
WO2016140878A2 (en) 2016-09-09
JP6700293B2 (ja) 2020-05-27
US20230381150A1 (en) 2023-11-30
PH12021550250A1 (en) 2022-09-05
WO2016140878A3 (en) 2016-11-24
IL253989A0 (en) 2017-10-31
JP7012117B2 (ja) 2022-02-10
CA2978158C (en) 2022-04-12
HRP20220208T1 (hr) 2022-04-29
AU2016226463A1 (en) 2017-09-21
DK3265448T3 (da) 2022-03-28
EA034759B1 (ru) 2020-03-17
BR112017018832A2 (pt) 2018-04-24
WO2016140879A1 (en) 2016-09-09
IL278080B (en) 2022-03-01
CN107567438A (zh) 2018-01-09
AU2022202163B2 (en) 2024-02-29
SG10201908354VA (en) 2019-10-30
US20230017637A1 (en) 2023-01-19
PH12017501576B1 (en) 2021-11-05
US10905681B2 (en) 2021-02-02
JP2020128401A (ja) 2020-08-27
AU2022202163A1 (en) 2022-04-21
HK1248706A1 (en) 2018-10-19
WO2016140879A9 (en) 2016-11-03
IL253989B (en) 2020-11-30
IL278080A (en) 2020-11-30
US11052070B2 (en) 2021-07-06
BR112017018832B1 (pt) 2023-12-26
EP3265448A4 (en) 2018-11-07
CY1125112T1 (el) 2024-02-16
LT3265448T (lt) 2022-04-11
WO2016140878A9 (en) 2016-10-20
CN107567438B (zh) 2021-06-29
EP3265448B1 (en) 2021-12-29
US10485791B2 (en) 2019-11-26
SI3265448T1 (sl) 2022-04-29
EA201791951A1 (ru) 2018-01-31
PT3265448T (pt) 2022-02-04
PH12017501576A1 (en) 2018-03-12
US20230381149A1 (en) 2023-11-30
US20240091205A1 (en) 2024-03-21
US20200085794A1 (en) 2020-03-19
HUE058204T2 (hu) 2022-07-28
EP3265448A1 (en) 2018-01-10
AU2020233650B2 (en) 2022-04-07
KR102587894B1 (ko) 2023-10-12
SG11201706831RA (en) 2017-09-28
MX2017011196A (es) 2018-05-22
US20200289475A1 (en) 2020-09-17
AU2020233650A1 (en) 2020-10-08
KR20230147746A (ko) 2023-10-23
US10639298B2 (en) 2020-05-05
US20180036290A1 (en) 2018-02-08
RS62915B1 (sr) 2022-03-31
CA2978158A1 (en) 2016-09-09
EP4011870A1 (en) 2022-06-15
KR20180008402A (ko) 2018-01-24
US20180037557A1 (en) 2018-02-08
US12005046B2 (en) 2024-06-11
US20210236471A1 (en) 2021-08-05
JP2018508525A (ja) 2018-03-29
MX380828B (es) 2025-03-12
US12005047B2 (en) 2024-06-11
AU2016226463B2 (en) 2020-06-25
US12213965B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
NO2025003I1 (no) Fidanacogene elaparvovec
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
IL293377A (en) Hsd17b13 variants and uses thereof
RS62164B1 (sr) Sulfoniluree i srodna jedinjenja i njihova upotreba
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
DK3283625T3 (da) Nukleasemedieret genomeditering
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania
KR20180084891A (ko) 구조 조성물 및 방법
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
DK3277719T3 (da) Polypeptider
DK3305788T3 (da) Janus-kinase-hæmmer
EP3350489A4 (en) VALVE AND COUPLING
DK3310450T3 (da) Olie-vand-separator
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3270930T3 (da) Præeklampsi
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
MA49905A (fr) Polyesteramines et polyesterquats
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3292136T3 (da) Penicillin-g-acylaser
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载